“CD47这个金矿,前几年全球范围内很多公司都在挖,但最后感觉像是陷入了沼泽。”宜明昂科(01541.HK)董事长田文志近期表示。 2020年左右,全球药企对CD47靶点趋之若鹜,将其视之为下一个PD-1。跨国药企吉利德、辉瑞等都为之投资巨大,中国至少二十家企业拿到临床批文。但全球药企巨额投资之后,纷纷偃旗息鼓,CD47靶点还没有诞生一颗药物。全球开发CD47靶点的企业已经寥寥无几,国际上辉瑞和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.